Stay updated with breaking news from Deciphera Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study - Deciphera Pharmaceuticals, Inc.
– Seventh Approval Worldwide for QINLOCK and First European Approval – ... | October 12, 2021
Seventh Approval Worldwide for QINLOCK and First European Approval - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor - read this article along with other careers information, tips and advice on BioSpace